Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Ivanhoe Electric Strengthens Management Team with Addition of Michelle Lammers as Chief Operating Officer and Daniel Worthy as Senior Vice President of Operations
-
Miivo Provides Corporate Update on Its Launch of Its AI CFO Products
-
Galloper Gold Retains New Valley Drilling for Its Glover Island Drill Program
-
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
-
Asante Updates M&I Resource to 4.6 Million Ounces at Bibiani and Chirano Gold Mines
-
Astec Reports Second Quarter 2026 Results
-
Telix to Host R&D Day in New York City on September 22, 2026
-
Orion Reports First Quarter Financial Results: Revenue Increases 32% to 25.7M, Net Income at $2M
-
Qarakal Quantum Cuts Qubit Requirements by 10X with New Pangaea Quantum Computing Architecture
-
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
-
The Kraft Heinz Company Declares Regular Quarterly Dividend of $0.40 Per Share
-
Aztec Drills 88.4 meters of 1.42 g/t Au and 14.58 g/t Ag (1.69 g/t AuEq) in First North Extension Step-Out Drilling at the Tombstone Project, Arizona
-
Rocky Shore Drills 15.0 metres of 2.04 g/t Au Including 5.0 metres of 3.85 g/t Au, Announces Discovery of the Lucky 13 Gold Zone
-
Global Education Communities Corp. Announces Executive Appointments and Leadership Updates
-
Galway Metals Reports Broad Gold Intercepts from Southwest Deposit, Including 2.6 g/t Over 48.0 Metres
-
As Smart Air Purifiers Dominate 2026 Tech Coverage, Glow Guardian Offers a Fan-Free, Lab-Tested Alternative
-
Sprott Announces Second Quarter 2026 Results
-
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
-
Climb Signs Distribution Agreement with Harmonic Security to Help Secure Mid-Market & Enterprise AI Adoption
-
BioCryst Reports Second Quarter 2026 Financial Results
-
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
-
J & J Snack Foods Reports Fiscal 2026 Third Quarter Results
-
Nebius appoints Lindsey Irvine as Chief Marketing Officer
-
Kraft Heinz Reports Second Quarter 2026 Results; Updates 2026 Full Year Outlook
-
SharkNinja Reports Second Quarter 2026 Results
-
Dine Brands Global, Inc. Reports Second Quarter 2026 Results
-
Cushman & Wakefield Reports Financial Results for the Second Quarter 2026
-
Lahontan Drills 12.2m Grading 1.25 g/t Au Oxide at Calvada East
-
Valvoline Inc. Reports Third Quarter Results
-
InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
-
REGAL REXNORD REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
-
C.H. Hanson Acquires Brodbeck Ironworks, Expanding Solutions for Metalworkers and Bladesmiths
-
Acacia Research Corporation Reports Second Quarter 2026 Financial Results
-
Charles River Laboratories Announces Second-Quarter 2026 Results
-
Caesarstone Reports Second Quarter 2026 Financial Results
-
Brink's Delivers Strong Second-Quarter Results
-
AEye Apollo™ Lidar Validated on NVIDIA DRIVE AGX Thor™
-
Forbes Travel Guide Expands; Mandarin Oriental Headlines Inaugural Debut Collection
-
Spire reports FY26 third quarter results
-
STX deploys Eventus Validus platform for trade surveillance
-
CDW Reports Second Quarter 2026 Earnings
-
Galaxy Announces Second Quarter 2026 Financial Results
-
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
-
Insulet Reports Second Quarter 2026 Results
-
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
-
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
-
Palmer Square Capital BDC Inc. Announces Second Quarter 2026 Financial Results
-
CRITEO REPORTS SECOND QUARTER 2026 RESULTS
-
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
-
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
